Vaccine against hepatitis A virus
AssigneeThe United States of America as represented by the Department of Health and Human Services
InventorsRobert H. Purcell, John R. Ticehurst, Jeffrey I. Cohen, Suzanne U. Emerson, Stephan M. Feinstone, Richard J. Daemer, Ian D. Gust
Life of this patent
Estimating the term…
Abstract
The present invention provides an attenuated hepatitis A virus useful as a vaccine.
Claims6
An attenuated hepatitis A virus comprising a genome characterized by the following nucleotides:
- cytosine at positions 3919, 4043, 4222 and 4810;
- guanine at positions 964 and 3196;
- adenine at positions 1742, 2864, 4185, 4563, 5204, 6147 and 6522;
- and thymine at positions 3025, 3889, 4087 and 5232.
A tissue culture adapted hepatitis A virus comprising a genome characterized by a cytosine at nucleotide position 3919 and a thymine at nucleotide position 3889.
A method for inducing protective immunity against HAV, comprising administering to a host susceptible to HAV infection, immunogenic amount of hepatitis A virus comprising a genome coding for alanine at nucleotide position 3919 and valine at nucleotide position 3889, to render said host immune to HAV infection.
Dependencies are inferred from the claim text.